Study guide
4.5 Polymorphic VT (Torsades de Pointes) & Magnesium Sulfate Protocol
AHA ACLS Provider Advanced Cardiovascular Life Support
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: BLS & High-Quality CPR Foundation
1.1 Chest Compression Mechanics & Performance Metrics 1.2 Chest Compression Fraction & Interruptions 1.3 Two-Rescuer Rotation & Fatigue Prevention 1.4 AED Operation & Special Resuscitation Circumstances
2 Chapter 2: ACLS Adult Cardiac Arrest Algorithm
2.1 Cardiac Arrest Recognition & Systematic Approach 2.2 VF/pVT Management & Defibrillation Energy Protocols 2.3 Asystole & PEA Management 2.4 Epinephrine Dosing & Pharmacodynamics in Arrest 2.5 Antiarrhythmic Drugs: Amiodarone & Lidocaine in Refractory VF/pVT 2.6 Reversible Causes of Arrest: The H's 2.7 Reversible Causes of Arrest: The T's 2.8 Physiological Monitoring & CPR Quality Metrics
3 Chapter 3: Bradycardia Algorithm
3.1 Symptomatic Bradycardia Assessment & Instability Criteria 3.2 Atropine Dosing, Indications & Block Limitations 3.3 Transcutaneous Pacing (TCP) Operation & Management 3.4 Chronotropic Infusion Therapies: Dopamine & Epinephrine
4 Chapter 4: Tachycardia Algorithm
4.1 Tachycardia Triage: Stable vs. Unstable Assessment 4.2 Synchronized Cardioversion Indications, Energy Doses & Sync Mechanics 4.3 Stable Narrow-Complex Tachycardia: Vagal Maneuvers & Adenosine Protocol 4.4 Stable Wide-Complex Tachycardia & Antiarrhythmic Infusions 4.5 Polymorphic VT (Torsades de Pointes) & Magnesium Sulfate Protocol
5 Chapter 5: Acute Coronary Syndrome (ACS)
5.1 ACS Identification, EMS & ED Triage 5.2 Initial ED & Prehospital Pharmacotherapy 5.3 STEMI vs. NSTE-ACS Risk Stratification & Biomarkers 5.4 Reperfusion Strategies & Quality Benchmark Time Goals
6 Chapter 6: Acute Ischemic Stroke
6.1 Stroke Recognition & Out-of-Hospital Assessment 6.2 Emergency Department Evaluation & Diagnostic Time Goals 6.3 Fibrinolytic Therapy & Blood Pressure Management 6.4 Endovascular Therapy (EVT) & Post-Acute Care
7 Chapter 7: Post–Cardiac Arrest Care
7.1 Immediate Post-ROSC Airway & Respiratory Optimization 7.2 Hemodynamic Management & MAP Optimization 7.3 Temperature Control & Targeted Temperature Management (TTM) 7.4 Emergent Coronary Angiography & Multimodal Neuroprognostication
8 Chapter 8: Airway Management & Pharmacology
8.1 Basic Airway Adjuncts & Bag-Mask Ventilation 8.2 Advanced Airways: Supraglottic Devices & Endotracheal Intubation 8.3 Continuous Waveform Capnography 8.4 ACLS Emergency Drug Reference & Administration Routes
9 Chapter 9: High-Performance Team Dynamics & Special Circumstances
9.1 High-Performance Team Dynamics & Communication 9.2 Resuscitation Debriefing & Quality Improvement Metrics 9.3 Special Arrest Circumstances: Cardiac Arrest in Pregnancy 9.4 Special Arrest Circumstances: Opioids, Anaphylaxis, Drowning & Hypothermia
4.5 Polymorphic VT (Torsades de Pointes) & Magnesium Sulfate Protocol
Key Takeaways Explain This Topic AI
Polymorphic VT exhibits continuously changing QRS amplitudes, vectors, and durations, rapidly degenerating into VF.
Torsades de Pointes is a specific subtype of Polymorphic VT triggered by early afterdepolarizations (EADs) in the setting of prolonged QT interval.
Unstable or pulseless Polymorphic VT must be treated with immediate unsynchronized high-energy defibrillation shocks.
Magnesium Sulfate (1-2 g IV over 15 minutes for stable Torsades with a pulse; 1-2 g IV push over 1-2 min for cardiac arrest) is first-line pharmacotherapy.
Adjunctive management requires repletions of potassium (target 4.5-5.0 mEq/L) and magnesium (>2.0 mg/dL), withdrawal of QT-prolonging drugs, and overdrive pacing or Isoproterenol.
Last updated: July 2026
4.5 Polymorphic VT (Torsades de Pointes) & Magnesium Sulfate Protocol
Polymorphic Ventricular Tachycardia (PVT) is a life-threatening, highly unstable ventricular arrhythmia characterized by QRS complexes that continuously vary in amplitude, axis, vector, and duration from beat to beat. On the cardiac monitor, the rhythm displays a chaotic, irregular sequence of wide QRS complexes that appear to twist continuously around the isoelectric line.
Unlike monomorphic Ventricular Tachycardia, which originates from a single fixed reentrant circuit or ectopic focus, polymorphic VT represents rapidly shifting ventricular depolarization pathways. It carries an extremely high risk of deteriorating into Ventricular Fibrillation (VF) or pulseless cardiac arrest.
Pathophysiology of Torsades de Pointes & The Long QT Connection
Torsades de Pointes ("twisting of the points") is a specific clinical subtype of polymorphic VT that occurs strictly in the presence of a prolonged baseline QT interval (typically QTc > 480 to 500 milliseconds).
The Mechanism of Early Afterdepolarizations (EADs)
The electrophysiological foundation of Torsades de Pointes rests on Early Afterdepolarizations (EADs) occurring during Phase 3 of the cardiac action potential:
Delayed Repolarization: When cardiac repolarization is abnormally prolonged (reflected on the ECG as a long QT/QTc interval), the duration of Phase 2 (plateau) and Phase 3 (repolarization) is extended.
Calcium Channel Reactivation: During this prolonged repolarization phase, L-type calcium channels ( I Ca,L I_{\text{Ca,L}} I Ca,L ) can spontaneously recover from inactivation and reactivate.
Triggered Activity: This inward calcium current creates membrane potential oscillations known as Early Afterdepolarizations. If an EAD reaches threshold potential before full repolarization is complete, it triggers a premature ventricular contraction (PVC).
Initiation of Torsades: When a triggered PVC falls on the prolonged, heterogeneous T-wave of a preceding beat (an "R-on-T" phenomenon), it initiates a self-sustaining, multiform reentrant circuit, manifesting as Torsades de Pointes.
Etiologies of Acquired Long QT Syndrome & Torsades de Pointes
Acquired long QT syndrome is the primary driver of Torsades de Pointes in acute care settings. The three main underlying causes are electrolyte disturbances, QT-prolonging medications, and severe bradycardia.
1. Electrolyte Imbalances
Electrolyte deficits delay repolarization and promote EAD formation:
Hypokalemia (<4.0 mEq/L): Reduces outward delayed rectifier potassium currents ( I Kr I_{\text{Kr}} I Kr ), significantly prolonging repolarization duration.
Hypomagnesemia (<2.0 mg/dL): Destabilizes membrane Na+/K+ ATPase activity and impairs inward rectifier potassium channels, dramatically lowering the threshold for EADs.
Hypocalcemia: Prolongs the Phase 2 plateau phase of the action potential.
2. QT-Prolonging Medications (High-Yield Board Topics)
Numerous pharmacological agents delay repolarization by blocking the I Kr I_{\text{Kr}} I Kr potassium channel. Common culprits include:
Antiarrhythmics: Class Ia (Procainamide, Quinidine, Disopyramide) and Class III (Sotalol, Dofetilide, Ibutilide, Amiodarone).
Psychotropics: Haloperidol, Chlorpromazine, Thioridazine, Tricyclic Antidepressants (TCAs), Selective Serotonin Reuptake Inhibitors (SSRIs like Citalopram and Escitalopram).
Antimicrobial Agents: Macrolides (Azithromycin, Erythromycin, Clarithromycin), Fluoroquinolones (Levofloxacin, Ciprofloxacin, Moxifloxacin), Antifungals (Fluconazole, Ketoconazole).
Other Agents: Methadone, Droperidol, Ondansetron (in high IV doses).
3. Bradycardia & Pause-Dependent Triggers
Severe sinus bradycardia, high-grade AV block, or compensatory pauses following premature ventricular contractions (PVCs) prolong the ventricular cycle length. Longer cycle lengths naturally lengthen the QT interval, creating a "long-short" ventricular sequence that precipitates EADs and Torsades.
Emergency Electrical Management: Unsynchronized Defibrillation
The electrical management of Polymorphic VT depends on patient stability, but unsynchronized defibrillation is the mandatory electrical mode.
Mandatory Electrical Protocol for Unstable or Pulseless Polymorphic VT
If the patient presenting with polymorphic VT or Torsades de Pointes is unstable (hypotensive, altered mental status, in shock, or pulseless):
Action: Deliver an immediate Unsynchronized High-Energy Shock (Defibrillation) .
Biphasic Defibrillator: 120 to 200 Joules (or maximum available energy setting).
Monophasic Defibrillator: 360 Joules.
Why Synchronized Cardioversion is Absolutely Contraindicated
A critical ACLS concept frequently tested on board exams is why synchronized cardioversion cannot be used for polymorphic VT :
In monomorphic VT, QRS complexes have uniform height and morphology, enabling the defibrillator's internal synchronization algorithm to accurately detect R-waves and time the shock.
In polymorphic VT and Torsades de Pointes, the QRS complexes continuously change in amplitude, axis, and shape from beat to beat. The defibrillator's sync tracking mechanism cannot lock onto a reliable R-wave peak.
If a provider attempts synchronized cardioversion on polymorphic VT, the device will either fail to discharge entirely (leaving the patient in lethal tachycardia) or discharge randomly on a T-wave, instantly precipitating Ventricular Fibrillation.
Therefore, polymorphic VT must always be treated with unsynchronized high-energy shocks (defibrillation) .
2025 AHA Guidelines: Pharmacotherapy — Magnesium Sulfate Protocol
Magnesium Sulfate is the first-line, definitive pharmacological agent for Torsades de Pointes, regardless of whether the patient's baseline serum magnesium level is normal or low.
Mechanism of Action
Magnesium acts as a natural calcium channel antagonist. It inhibits inward L-type calcium currents ( I Ca,L I_{\text{Ca,L}} I Ca,L ), directly suppressing Early Afterdepolarizations (EADs) and terminating Torsades de Pointes without significantly altering the baseline QT duration.
Dosing Protocol for Stable Torsades de Pointes (Patient With a Pulse)
Dose: 1 to 2 grams IV/IO .
Dilution: Dilute 1 to 2 grams of Magnesium Sulfate in 10 mL of 5% Dextrose in Water (D5W) or 0.9% Normal Saline.
Infusion Duration: Administer as a slow IV infusion over 15 minutes .
Dosing Protocol for Pulseless Torsades de Pointes (Cardiac Arrest / Crashing Unstable)
Dose: 1 to 2 grams IV/IO .
Administration Method: Administer as a rapid IV/IO push over 1 to 2 minutes during ongoing CPR.
Post-Conversion Maintenance Infusion
If Torsades recurs after initial bolus therapy, initiate a continuous IV maintenance infusion of 0.5 to 1 gram per hour .
Comprehensive Adjunctive & Preventive Interventions
Terminating the acute episode of Torsades de Pointes is only the first step. Preventing recurrence requires aggressive adjunctive management:
Replete Serum Electrolytes:
Potassium Target: Aggressively replete serum potassium to maintain levels at 4.5 to 5.0 mEq/L .
Magnesium Target: Maintain serum magnesium levels at >2.0 mg/dL (>1.0 mmol/L).
Withdraw Offending Medications: Immediately review the patient's medication list and stop all QT-prolonging drugs.
Overdrive Pacing & Isoproterenol Infusion (For Pause-Dependent Torsades):
Physiological Basis: Increasing the baseline heart rate shortens the QT interval and repolarization duration, abolishing pause-dependent EADs.
Electrical Overdrive Pacing: Perform transcutaneous or transvenous overdrive pacing at a target rate of 90 to 110 beats per minute .
Isoproterenol Infusion: Administer a continuous IV infusion of Isoproterenol (a pure beta-1/beta-2 agonist) at 2 to 10 mcg/min , titrated to maintain a heart rate >90 bpm. Caution: Isoproterenol is indicated strictly for non-ischemic pause-dependent Torsades; it is contraindicated in acute coronary syndrome.
Comparative Management Summary: Monomorphic vs. Polymorphic VT
- Feature Monomorphic VT Polymorphic VT (Torsades de Pointes)
- QRS Morphology Uniform, consistent beat-to-beat Varying amplitude, axis, twisting vector
- Baseline QT Interval Usually normal Prolonged (QTc >480–500 ms in TdP)
Unstable Electrical Therapy Synchronized Cardioversion (100 J biphasic) Unsynchronized Defibrillation (120–200 J biphasic)
First-Line Antiarrhythmic Procainamide (20–50 mg/min) or Amiodarone (150 mg/10 min) Magnesium Sulfate (1–2 g IV over 15 min)
Contraindicated Drugs Calcium channel blockers (Verapamil, Diltiazem) Antiarrhythmics that prolong QT (Procainamide, Sotalol, Amiodarone)
Adjunctive Therapy Treat underlying ischemia / structural heart disease Replete K+ (4.5–5.0) & Mg+ (>2.0), Overdrive Pacing (90–110 bpm)
High-Yield Exam Pearls for Polymorphic VT & Torsades
Unsynchronized Shocks Required: Unstable polymorphic VT cannot be synchronized. Always shock in defibrillation mode!
Magnesium Dosing: 1–2 g IV over 15 min for stable TdP with a pulse; 1–2 g rapid IV push for pulseless TdP.
Avoid Procainamide & Amiodarone in TdP: These drugs prolong QT and will worsen Torsades de Pointes.
Overdrive Pacing: Increasing HR to 90–110 bpm shortens QT interval and suppresses Torsades.